Delivery Order SPE2DB20D3111-SPE2DB25FA9AF
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $5,028.93. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania, and carries an ultimate completion date of August 12, 2025. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $3,532.41. This competitive award, utilizing firm fixed-price terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $12,991.41 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 30, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $77,218.07. This is a firm fixed price, non-competitive delivery order to be completed by July 31, 2025. The contract is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $20,573.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is categorized as a child contract under AmerisourceBergen's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $24,690.56 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award to the pharmaceutical distributor for delivery to the Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $28,942.08. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as a...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $16,554.78 for 60 tablets of Xifaxan 550 mg under a non-set-aside, competitively awarded contract with the Defense Logistics Agency's Medical Supply Chain division. The contract employs firm fixed price pricing and carries an ultimate completion date of August 22, 2025, with the award issued on August 21, 2025. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $10,087.24 firm fixed-price contract provides the DLA with 4,563,517,205 units of the drug Xifaxan 550 mg tablets. The contract has a completion date of February 2, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA9AFDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $7,318.28. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 22, 2025. The contract is issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999.00 global pharmaceutical supply vehicle valued through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a broad range of pharmaceutical products and medical commodities to support military and veteran healthcare systems. The DLA, operating under the Department of Defense, utilizes AmerisourceBergen's prime vendor contract to fulfill pharmaceutical needs across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Xifaxan, an antibiotic medication, exemplifies the company's role in providing specialized pharmaceutical support to federal military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 8/21/25 |